515,059 Shares in Emergent Biosolutions Inc. $EBS Purchased by Palisade Capital Management LP

Posted by Francis Steltz on Aug 26th, 2026

Palisade Capital Management LP purchased a new stake in Emergent Biosolutions Inc. (NYSE:EBS – Free Report) during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 515,059 shares of the biopharmaceutical company’s stock, valued at approximately $4,316,000. Palisade Capital Management LP owned about 1.00% of Emergent Biosolutions as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also recently bought and sold shares of the company. CWM LLC lifted its position in Emergent Biosolutions by 5.5% during the fourth quarter. CWM LLC now owns 18,009 shares of the biopharmaceutical company’s stock worth $223,000 after acquiring an additional 942 shares during the last quarter. Franklin Resources Inc. grew its position in shares of Emergent Biosolutions by 2.3% in the fourth quarter. Franklin Resources Inc. now owns 78,945 shares of the biopharmaceutical company’s stock valued at $976,000 after purchasing an additional 1,764 shares during the last quarter. SG Americas Securities LLC increased its stake in shares of Emergent Biosolutions by 4.6% during the first quarter. SG Americas Securities LLC now owns 42,394 shares of the biopharmaceutical company’s stock worth $352,000 after purchasing an additional 1,865 shares during the period. Deutsche Bank AG lifted its holdings in Emergent Biosolutions by 1.1% during the 4th quarter. Deutsche Bank AG now owns 181,744 shares of the biopharmaceutical company’s stock worth $2,246,000 after purchasing an additional 1,941 shares during the last quarter. Finally, Values First Advisors Inc. lifted its holdings in Emergent Biosolutions by 0.9% during the 1st quarter. Values First Advisors Inc. now owns 307,880 shares of the biopharmaceutical company’s stock worth $2,555,000 after purchasing an additional 2,834 shares during the last quarter. 78.40% of the stock is owned by institutional investors.

Emergent Biosolutions Trading Up 8.9%

Shares of NYSE:EBS opened at $5.64 on Wednesday. The business’s 50 day simple moving average is $7.00 and its 200 day simple moving average is $8.17. Emergent Biosolutions Inc. has a 1 year low of $4.36 and a 1 year high of $14.06. The company has a debt-to-equity ratio of 1.70, a current ratio of 5.42 and a quick ratio of 2.95. The company has a market capitalization of $289.27 million, a P/E ratio of -1.59 and a beta of 2.35.

Emergent Biosolutions (NYSE:EBS – Get Free Report) last announced its quarterly earnings data on Wednesday, August 5th. The biopharmaceutical company reported $0.60 earnings per share for the quarter, beating the consensus estimate of ($0.08) by $0.68. Emergent Biosolutions had a positive return on equity of 16.35% and a negative net margin of 22.95%.The firm had revenue of $234.30 million during the quarter, compared to analysts’ expectations of $177.50 million. On average, research analysts anticipate that Emergent Biosolutions Inc. will post -4.63 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

EBS has been the topic of a number of research reports. UBS Group reaffirmed a “buy” rating on shares of Emergent Biosolutions in a report on Tuesday, June 2nd. HC Wainwright dropped their target price on Emergent Biosolutions from $12.00 to $10.00 and set a “buy” rating for the company in a report on Monday, August 10th. Benchmark reissued a “buy” rating on shares of Emergent Biosolutions in a research report on Tuesday, June 2nd. Weiss Ratings upgraded shares of Emergent Biosolutions from a “sell (d-)” rating to a “sell (d)” rating in a research note on Friday. Finally, Zacks Research raised shares of Emergent Biosolutions to a “hold” rating in a research report on Tuesday, August 11th. Three research analysts have rated the stock with a Buy rating, one has given a Hold rating and two have issued a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $10.00.

View Our Latest Analysis on Emergent Biosolutions

Insider Transactions at Emergent Biosolutions

In other Emergent Biosolutions news, SVP Paul Anthony Williams sold 3,000 shares of the stock in a transaction dated Wednesday, July 1st. The shares were sold at an average price of $8.40, for a total transaction of $25,200.00. Following the sale, the senior vice president directly owned 159,098 shares in the company, valued at $1,336,423.20. This represents a 1.85% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 6.00% of the stock is owned by insiders.

Emergent Biosolutions Company Profile

(Free Report)

Emergent BioSolutions is a global specialty biopharmaceutical company focused on developing, manufacturing and commercializing medical countermeasures and specialty products that address public health threats. The company’s portfolio includes vaccines, antibody therapies and critical care products designed to protect against biological, chemical and emerging infectious disease threats. Emergent has longstanding partnerships with government agencies, including the U.S. Department of Defense and the Biomedical Advanced Research and Development Authority (BARDA), to support national preparedness programs.

Key commercial products in Emergent’s lineup include BioThrax (anthrax vaccine adsorbed), ACAM2000 (smallpox vaccine) and Vaxchora (cholera vaccine), alongside therapeutic treatments such as Anthrasil (anthrax immune globulin) and the naloxone-based nasal spray Narcan for opioid overdose reversal.